MYD88 and cancer: Although targeted ablation of the PERK arm of the UPR exacerbates cancer cachexia in mice [39], inhibition of XBP1, a downstream target of TLR‐MYD88 signalling and the IRE1α arm of the UPR ameliorated cancer‐induced muscle wasting [40].